Form 4: Unicycive Therapeutics CEO Granted 325,000 Stock Options
Insider Transaction Report
Unicycive Therapeutics, Inc. CEO Shalabh K. Gupta was granted 325,000 stock options with an exercise price of $4.71, aligning executive incentives with long-term shareholder value.
Summary
- Shalabh K. Gupta, CEO and Director of Unicycive Therapeutics, Inc. (UNCY), was granted 325,000 stock options.
- The options have an exercise price of $4.71 per share.
- The grant date for these options was July 28, 2025, and they are set to expire on July 28, 2035.
- The vesting schedule includes 81,250 options vesting on July 28, 2026, with the remaining 243,750 options vesting at a rate of 1/36th per month thereafter.
- Following this transaction, Mr. Gupta beneficially owns 968,951 derivative securities.
Sentiment
Score: 6
Explanation: The grant of stock options to the CEO is generally a neutral to slightly positive event, as it aligns management incentives with long-term shareholder value. It does not reflect immediate financial performance but rather a compensation structure.
Positives
- The grant of stock options to the CEO aligns management's long-term interests with those of shareholders, as the options gain value only if the stock price increases above the exercise price.
- The significant number of options (325,000) indicates a substantial incentive for the CEO to drive company performance.
Future Outlook
The vesting schedule for the granted stock options extends over several years, with an initial tranche vesting in July 2026 and the remainder vesting monthly thereafter, indicating a long-term incentive structure for the CEO.
Industry Context
This Form 4 filing details a standard executive compensation event within the biotechnology or pharmaceutical industry, where stock options are a common tool to incentivize leadership and align their financial interests with company performance and shareholder returns.
Related Party Transactions
- The grant of 325,000 stock options to Shalabh K. Gupta, the CEO and a Director, constitutes a related party transaction as it involves compensation provided by the company to a key executive.
Stakeholder Impact
- Shareholders: The grant of options could lead to future dilution if exercised, but it also aims to align the CEO's interests with increasing shareholder value.
- Employees: No direct impact on other employees is mentioned, but it sets a precedent for executive compensation.
Next Steps
- Continued vesting of the 325,000 stock options according to the specified schedule.
- Potential exercise of vested options by Shalabh K. Gupta in the future.
Key Dates
| Date | Description |
|---|---|
| 07/28/2025 | Date of stock option grant and earliest transaction date. |
| 07/30/2025 | Date the Form 4 was signed by Shalabh K. Gupta. |
| 07/28/2026 | Date when 81,250 stock options will vest. |
| 07/28/2035 | Expiration date of the granted stock options. |
Keywords
Unicycive Therapeutics, UNCY, Shalabh K. Gupta, Stock Options, CEO Compensation, Insider Transaction, SEC Form 4, Executive Compensation, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.